HPV-Linked Oral Cancers Surge in Men as Cervical Cases Decline

While HPV vaccination has sharply reduced cervical cancer in women, oropharyngeal cancers tied to the virus are rising, particularly among middle-aged and older men. Studies show U.S. cases of HPV-related throat and mouth cancers more than tripled from 1988 to 2004, with a similar tripling seen in Denmark from 2000 to 2017. The trend is driven by high-risk HPV strains transmitted through oral sex, which can persist and cause DNA damage leading to cancer.

EXPANDED:

The gender gap in HPV-related oropharyngeal cancers is pronounced, with men receiving roughly 13,600 new diagnoses annually compared to 2,400 in women. These malignancies develop at the back of the throat, near the tonsils and tongue base, and are primarily driven by high-risk strains 16 and 18, which account for most HPV-attributable cancers across all sites.

Most sexually active adults will encounter HPV at some point, though immune systems typically clear the infection within one to two years. For individuals where the virus persists, it can inflict DNA damage that accumulates into malignancy. While cervical cancer prevention has advanced through vaccination